This promotional website is for UK Healthcare Professionals involved in the management of haematological malignancies. Adverse event reporting information can be found below.
Downloadable materials for your patients
Below are links to downloadable materials that may be useful as a resource to pass onto your patients who have been prescribed Venetoclax.
Patient guide for VEN + O
UK-VNCCLL-250094
Patient guide for VEN + R
UK-VNCCLL-250041
Patient guide for VEN in all lines
UK-VNCCLL-250061
Patient guide for VEN + I
UK-VNCCLL-250106
VEN+O dosing chart
UK-VNCCLL-240458
Ven+R dosing chart
UK-VNCCLL-240460
VEN+I dosing chart
UK-VNCCLL-250093
A guide to completing treatment with VENCLYXTO
UK-VNCCLL-250058
Dosing & Administration Guide
UK-VNCCLL-250097
Understanding patients perspectives
Seeing things from the patient perspective is an important aspect of patient-centered care. Our video featuring patient perspectives and stories illustrating the CLL treatment journey is here to view.
1L, 1st line; CLL, Chronic lymphocytic leukaemia; I, Ibrutinib; O, Obinutuzumab; R, Rituximab; R/R, Relapsed/Refractory; VEN, VENCLYXTO.
You are advised to read the Prescribing Information and Summary of Product Characteristics to evaluate patient suitability for VENCLYXTO.
VENCLYXTO PRESCRIBING INFORMATION
By clicking the link above you will leave the AbbVie Pro website and be taken to the eMC PI portal website.
VENCLYXTO SUMMARY OF PRODUCT CHARACTERISTICS
UK-VNCCLL-250218. Date of preparation: June 2025.
